Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.85 |
| ▸ | PSMB1 | P20618 | 6/20 | 0.76 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.76 |
| ▸ | PSMB2 | P49721 | 6/20 | 0.76 |
| ▸ | LTA4H | P09960 | 7/20 | 0.68 |
| ▸ | ESR1 | P03372 | 1/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL227588 | 1.00 | HRH3 (0.85) | HRH3PSMB1PSMB5PSMB2LTA4H | |
| SCHEMBL8973201 | 0.98 | HRH3 (0.82) | HRH3PSMB1PSMB5PSMB2LTA4H | |
| Hydroxyamine SCHEMBL6816656 | 0.97 | HRH3 (0.80) | HRH3PSMB1PSMB5PSMB2LTA4H | |
| SCHEMBL4089206 | 0.92 | HRH3 (1.00) | HRH3 | |
| SCHEMBL6657187 | 0.87 | HRH3 (0.86) | HRH3PSMB1PSMB5PSMB2LTA4H | |
| SCHEMBL12128339 | 0.87 | HRH3 (0.85) | HRH3 | |
| SCHEMBL17826374 | 0.87 | PSMB1 (0.71) | HRH3PSMB1PSMB5PSMB2LTA4H | |
| SCHEMBL9056254 | 0.85 | HRH3 (0.83) | HRH3PSMB1PSMB5PSMB2LTA4H | |
| SCHEMBL30777699 | 0.85 | HRH3 (1.00) | HRH3PSMB1PSMB5PSMB2LTA4H | |
| SCHEMBL3580727 | 0.85 | HRH3 (1.00) | HRH3PSMB1PSMB5PSMB2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022110-A1 | DIARYLACETYLENE COMPOUND, PREPARATION METHOD THEREOF, AND USES THEREOF | HENAN RADIOMEDICAL SCIENCE AND TECH CO LTD (CN) | 2026-01-22 | — | — | US | disclosed |
| WO-2024217219-A1 | DIARYLACETYLENE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 河南省锐达医药科技有限公司 | 2024-10-24 | — | — | WO | disclosed |
| CN-117447468-A | Bazedoxifene derivative and preparation method and application thereof | 中国药科大学 | 2024-01-26 | — | — | CN | disclosed |
| US-20230331676-A1 | NAPHTHYLUREA COMPOUND, METHODS OF PREPARATION AND USE THEREOF | HENAN RADIOMEDICAL SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331676-A1 | NAPHTHYLUREA COMPOUND, METHODS OF PREPARATION AND USE THEREOF | HENAN RADIOMEDICAL SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331676-A1 | NAPHTHYLUREA COMPOUND, METHODS OF PREPARATION AND USE THEREOF | HENAN RADIOMEDICAL SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230271928-A1 | NAPHTHYLUREA COMPOUND, METHODS OF PREPARATION AND USE THEREOF | HENAN RADIOMEDICAL SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271928-A1 | NAPHTHYLUREA COMPOUND, METHODS OF PREPARATION AND USE THEREOF | HENAN RADIOMEDICAL SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271928-A1 | NAPHTHYLUREA COMPOUND, METHODS OF PREPARATION AND USE THEREOF | HENAN RADIOMEDICAL SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| CN-113444035-B | Naphthyl urea compounds with anticancer effect and preparation method and application thereof | 河南省锐达医药科技有限公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-1082319-A1 | BENZOCARBAZOL AND INDENOINOLE DERIVED ESTROGENIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-03-14 | — | — | EP | disclosed |
| US-6159959-A | Combined estrogen and antiestrogen therapy | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| US-6107292-A | HORMONE REPLACEMENT THERAPY | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-08-22 | — | — | US | disclosed |
| EP-1025077-A1 | NOVEL ARYLOXY-ALKYL-DIALKYLAMINES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-08-09 | — | — | EP | disclosed |
| US-6069153-A | HORMONE REPLACEMENT THERPAY | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-05-30 | — | — | US | disclosed |
| US-6005102-A | NOVEL INTERMEDIATES WHICH MAY BE USED IN THE PRODUCTION OF PHARMACEUTICAL COMPOUNDS FOR ANTI-ESTROGENIC AND MATRIX METALLOPROTEINASES-INHIBITING UTILITIES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-21 | — | — | US | disclosed |
| WO-1999058524-A1 | BENZOCARBAZOLE AND INDENOINDOLE DERIVED ESTROGENIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-18 | — | — | WO | disclosed |
| WO-1999019293-A1 | NOVEL ARYLOXY-ALKYL-DIALKYLAMINES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-04-22 | — | — | WO | disclosed |
| EP-0832880-A1 | Dihydrobenzofluorene compounds, intermediates, compositions, and methods | ELI LILLY AND COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997030709-A1 | BENZOTHIOPHENES, FORMULATIONS CONTAINING SAME, AND METHODS | ELI LILLY AND COMPANY (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022110-A1 | DIARYLACETYLENE COMPOUND, PREPARATION METHOD THEREOF, AND USES THEREOF | STAT3, STAT6, CA2 | HRH3 2385/4885PSMB1 4648/4885PSMB5 4708/4885 |
| US-20230331676-A1 | NAPHTHYLUREA COMPOUND, METHODS OF PREPARATION AND USE THEREOF | NPM1, NCL, NOC2L | HRH3 1083/4885PSMB1 1410/4885PSMB5 2078/4885 |
| US-20230271928-A1 | NAPHTHYLUREA COMPOUND, METHODS OF PREPARATION AND USE THEREOF | C1R, C9, H1-3 | HRH3 63/4885PSMB1 2606/4885PSMB5 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.